FDBusiness.com

Nestlé Takes Stake in US Biopharmaceutical Company

 Breaking News
  • Lidl Becomes the UK’s Seventh Largest Supermarket The latest grocery market share figures from Kantar Worldpanel, for the 12 weeks ending 13 August 2017, show Lidl has increased its market share to a new record high of 5.2% – up 0.7 percentage points year on year – to become the UK’s seventh largest grocer. Fraser McKevitt, head of retailer and consumer insight at [...]...
  • 2 Sisters Plans Investment in Welsh Plant Britain’s biggest food manufacturer, 2 Sisters Food Group, has announced plans to expand supply from its Welsh processing facility in Merthyr Tydfil. The £1.4 million investment in the beef and sheep plant will be spent on modernising the beef boning hall and improving efficiency, quality and process control. Ranjit Singh, chief executive of 2 Sisters Food [...]...
  • Towards a Fairer Food Supply Chain – European Commission Asks For Input The European Commission is launching an EU-wide public consultation on how to make the EU food supply chain fairer. Farmers, citizens and other interested parties are invited to share their views on the functioning of the food supply chain through an online consultation that runs until 17 November. There are indications that the added value [...]...
  • Bord Bia Leads First Irish Presence at Japan International Seafood & Technology Expo Bord Bia (Irish Food Board) and Irish seafood exporters will exhibit for the first time at Japan International Seafood and Technology Expo in Tokyo  determined that its extensive market insight and promotion activity in South East Asia will lead to new business opportunities. The Bord Bia seafood strategy of expanding into emerging markets and maintaining its strong position in [...]...
  • New Video Guide to WCB Universal Twin Screw Pumps SPX FLOW is committed to providing excellent support and ensuring customers get the most from their equipment. As part of this regime, a series of maintenance videos have been created which provide clear, step-by-step guides to the correct maintenance procedures for SPX FLOW pumps, valves and other products. Properly maintaining equipment is an essential part [...]...
  • World’s Most Modern Snack Plant Begins Operations in Finland The world’s most modern dairy snack plant has commenced operation at Valio Riihimäki in Southern Finland. The snack plant is the largest single investment in Valio’s history. Construction of the new snack plant began in 2014 and took about three years. The area of the plant building is approximately 20,000 square metres. The plant is [...]...

Nestlé Takes Stake in US Biopharmaceutical Company

Nestlé Takes Stake in US Biopharmaceutical Company
November 04
14:32 2016

Nestlé Health Science is to invest $145 million for a 15% stake in US-based Aimmune Therapeutics, a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The parties also entered into a strategic collaboration to accelerate the development of innovative oral immunotherapy biologics designed to desensitize people with food allergies and protect them from the consequences of accidental exposure.

Up to 250 million people globally are estimated to suffer from food allergies, between 5-8% of children and 1-2% of adults. Amongst the top eight food allergies, peanut allergy – generally a lifelong condition – is estimated to impact 6 million people in the US and in Europe or between 0.6 and 1.3% of the population in the US.

Aimmune’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach to treating life-threatening food allergies is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. It aims to provide a transformative treatment option that goes beyond the current standard of care of diligent avoidance of food allergens and carrying epinephrine for administration in case of accidental exposure.

NestleHealthScienceLicenseAgreementAimmune’s lead CODIT product candidate, AR101 for peanut allergy, is a characterized, regulated, oral biological drug product containing the protein profile found in peanuts designed to desensitize patients with peanut allergy. The ongoing Phase III trial, conducted by Aimmune, is expected to deliver results in 4Q2017, which – if positive – may support the filing of marketing authorization in the US and Europe. Per the terms of this collaboration agreement, Aimmune retains the rights to AR101 and all other pipeline assets developed with the CODIT approach.

The investment extends Nestlé Health Science’s interests in the food allergy arena. Nestlé Health Science already has an established portfolio of nutritional solutions for pediatric food allergy and intolerances, especially Cow’s Milk Protein Allergy (CMPA), as well as a simple, fast and easy-to-use awareness tool – CoMiSS® (Cow’s Milk-related Symptom Score) – which enables primary healthcare professionals to earlier recognize and assess symptoms that may be related to CMPA in infants. Earlier this year the company partnered with DBV Technologies on the development of a skin-patch test tool for the improved diagnosis of CMPA.

Greg Behar, chief executive of Nestlé Health Science, who will take a seat on the Aimmune Board, comments: “Food allergies have a huge personal impact and are a health economic burden. We are investing and innovating to change the approach to food allergy management with integrated approaches from diagnostics (Dx), to nutrition solutions (Nx) and now biologics (Rx), where Aimmune’s proprietary approach has transformational potential in lives of patients and families.”

The strategic investment launches a two-year strategic collaboration between Nestlé Health Science and Aimmune, the terms of which enable the parties to engage on Aimmune’s current and future oral immunotherapy development programs through a newly established pipeline forum. Nestlé Health Science will provide ongoing scientific, regulatory and commercial expertise and advice to Aimmune through the pipeline forum and in addition has a three-month exclusive right of first negotiation for any development program in the event Aimmune considers licensing or partnering such a program.

About Author

mike

mike

Related Articles



Food & Drink Business Conference & Exhibition 2016

Upcoming Events

  • September 11, 2017drinktec
  • September 13, 2017FI Asia
  • September 19, 2017PROCESS EXPO 2017
  • September 22, 2017Global Summit on Food & Beverages
AEC v1.0.4

The Magazine

F&D Business Preferred Suppliers

Advertisements